Clinical Data Manager

Clinical Data Manager

Support data deliverables for clinical studies and work with the Clinical Data Management processes, standards, and technology.

Owlstone Medical is a growing company with a mission to save 100,000 lives and $1.5 billion in healthcare costs through Breath Biopsy. Breath Biopsy is a unique technology that analyses exhaled breath to identify biomarkers of disease, enabling the early detection of disease and providing an avenue for precision medicine, making Owlstone the leader in the industry of breath research.

Developing Breath Biopsy is a team of scientists, doctors, engineers, and entrepreneurs predominantly based in Owlstones head office on the Cambridge Science Park, with several staff working from other locations, including the US. In 2004 Owlstone Inc spun out of the University of Cambridge, with the original goal of developing the use of field asymmetric ion mobility spectroscopy (FAIMS). One of the co-founders is engineering graduate Billy Boyle who was interested in the medical applications of FAIMS technology after his late wife had a late diagnosis of colon cancer. Billy worked with clinical partners who integrated FAIMS technology across a range of disease research studies and secured $7 million in funding to launch Owlstone Medical in 2016, of which he is now the founding CEO.

Owlstone Medical has now secured over $150 million in investment and has developed Breath Biopsy to create non-invasive breath tests to support the early detection and precision medicine of diseases including cancer, liver disease, asthma, and more. AstraZeneca, Johnson and Johnson, and Glaxo Smith Kline are just a few of the leading academic institutions and industry leaders that Owlstone Medical works alongside to achieve its mission.

Breath Biopsy technology presents exciting possibilities. It is used for academic, clinical, and pharmaceutical research at sites all over the world, and it is just getting started on its potential. In 2023, Owlstone Medical launched OMED Health, a dedicated, patient-centric brand, and digital platform that offers patients and clinicians access to breath-based diagnostic tests, point-of-care devices, and resources for a range of gastrointestinal conditions. OMED Health helps individuals with gut health issues have an improved quality of life by enabling better, and faster, understanding and management of their conditions. In the last 12 months,  Owlstone has entered a partnership with the US Department of Defence to develop handheld Breath Biopsy devices for early infectious disease detection, as well as a partnership with Bicycle Therapeutics to develop antigen-targeting exogenous volatile organic compound probes for the early detection of cancer.

Owlstone says: “We are on the lookout for people to join us as we tackle the scientific, engineering, and commercial challenges to achieve our mission of saving 100,000 lives and $1.5 billion in healthcare costs with Breath Biopsy. We currently balance providing world-leading services that support breath research, with conducting our internal studies to develop new breath tests and creating tools and technologies that will enable easy-access breath testing in the clinical setting. We reward dedication, dynamism, and ability with a competitive salary, share options, and an array of benefits.”

At Owlstone Medical, everyone makes a difference. Join the company to develop Breath Biopsy technology today, to revolutionize healthcare tomorrow.

• Apply at https://www.owlstonemedical.com/about/careers/opportunities/